Sales & Earnings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
After recently rebranding the company, Neuraxpharm has put expansion plans in place that have allowed it to reach over 70% of the European central nervous system market, resulting in projections of organic sales growth of 10% and gross sales of €400m for this year.
Glenmark says its reorganization into three entities – one focused on generics and specialty drugs, the second on APIs and the third on new drug innovation – will be wrapped up by year-end as it seeks to accelerate sluggish earnings and reduce heavy debt.
Having swelled its pipeline of US injectable drugs through an acquisition, ANI Pharmaceuticals is on the lookout for attractive manufacturing assets.
Luye Pharma says it is making sound progress in developing a pipeline of added-value injectables and transdermal patches, while clinical trials for two biosimilars are also moving forward.
As it struggles to restore exports to one of its key markets, Saudi Arabia, following a facility inspection, UAE-based Julphar is continuing to post large losses on tumbling turnover.
Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.